Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2024 Jan 25.

Published in final edited form as: Mol Cell Biochem. 2020 Jan 7;466(1-2):1–15. doi: 10.1007/s11010-019-03680-y

Fig. 4 — Both MCs (a, c) and MGECs (b, d) were treated with or without Ang-II for 48 h. GYY (GYY4137) was added 1 h prior to the Ang-II treatment. MMP-13 protein (~53 kDa) and gene expressions of were determined by Western blot and RT-PCR, respectively (a, b). GAPDH was used as a loading control. Data are presented as mean ±SEM, n = 9 independent experiments / group. *p <0.05 vs control, ^†p <0.05 vs Ang-II. Scale bar, 20 μm, magnification 60 X. (c, d) cells were immunostained against MMP-13 (red), and nuclei counterstained with DAPI (blue). (e) and (f) summarized data of MMP-13 expression as observed in immunostaining of MCs and MGECs, respectively. Data are presented as mean ± SEM, n=9 independent experiments / group. *p <0.05 vs control, †p <0.05 vs Ang-II.

Fig. 4 — Both MCs (a, c) and MGECs (b, d) were treated with or without Ang-II for 48 h. GYY (GYY4137) was added 1 h prior to the Ang-II treatment. MMP-13 protein (~53 kDa) and gene expressions of were determined by Western blot and RT-PCR, respectively (a, b). GAPDH was used as a loading control. Data are presented as mean ±SEM, n = 9 independent experiments / group. *p <0.05 vs control, ^†p <0.05 vs Ang-II. Scale bar, 20 μm, magnification 60 X. (c, d) cells were immunostained against MMP-13 (red), and nuclei counterstained with DAPI (blue). (e) and (f) summarized data of MMP-13 expression as observed in immunostaining of MCs and MGECs, respectively. Data are presented as mean ± SEM, n=9 independent experiments / group. *p <0.05 vs control, †p <0.05 vs Ang-II.